Visionix USA announced the launch of its latest addition to a product line of fundus imaging cameras: the VX 610, a non-mydriatic automated fundus camera.
Let’s start with this company.
The Lombard, Illinois-based medical equipment manufacturer develops core refractive, screening, and imaging technologies for eyecare professionals (ECPs).
Notable among its products is the Optovue line of optical coherence tomography (OCTs), as well as a broad range of technologies in the following categories:
- Automatic lens edgers
- Automatic lensmeters
- Autorefractometers
- Fundus cameras (our topic of discussion)
- Refraction
- Screening
- Slit lamps
Now these fundus cameras.
The company currently offers two products in this category:
- Visionix NEXY Artificial intelligence (AI)*
- Note: This camera is not available in the U.S.
- VX 610*
Both cameras are marketed as using state-of-the-art, fully automated equipment to deliver fundus images with high resolution and sensitivity plus a wide field of observation.
Zero in on the VX 610.
As Visionix’s second fundus camera, the VX 610 provides a trio of automated capabilities—auto alignment, autofocus, and autocapture—intended to streamline the imaging process and reduce errors.
As a bonus: Designed with a modern, small footprint for the clinical practice, this camera also offers a 45° field of view and a 90° mosaic function.
And its key features?
Like the NEXY AI*, the VX 610 is equipped with a few key features:
- Cross-polarized light technology for high-quality imaging
- A compact footprint
- Early automatic detection of 13+ retinal pathologies
- Unlike the NEXY AI, this is capable via the VX 610 AI EyeWisdom MCS solution (see below for details).
Talk about the VX 610 AI EyeWisdom MCS solution.
Utilized as part of Visionix’s telehealth, AI-based retina screening*, this solution entails a 2-minute screening of both eyes and 1 minute to receive AI feedback for early suspect detection (followed by human grading to verify).
Per the company, the technology has been clinically “assessed and validated comparing the outcome of the algorithm to the opinion and diagnosis of experienced ophthalmologists.”
- To note: Included among the 13 detectable retinal conditions are:
- Dry/wet age-related macular degeneration (AMD)
- Glaucoma
- Diabetic retinopathy (DR)
Related: Read up on the company’s recent ocular telemedicine and tele-optometry partnership with 20/20NOW to offer DR screenings.
Now back to these features.
Just a few more:
- Non-mydriatic retinography
- Enables observing, capturing, and recording high-definition without the no need for fundus dilation via the pupil
- AI sensitivity and specificity*
- Visionix reports a 93% and 90.6% capability to tag a positive and negative result, respectively
- Automatic image capturing
- Produces detailed screening and evaluations—with a reduced need for personal training
- Touch-screen interface
- Intended for clinicians to quickly start and efficiently navigate the camera
Note: Computer grading is not available for the VX 610 in the United States.
Nice! So where can I test this out?
Are you attending Vision Expo West (VEW; Sept. 19-21 in Las Vegas, Nevada) next month?
If so, the company will be featuring the VX 610 at its booth (#F10065)—among other refraction and screening tech products like Optovue and Briot/Weco lens finishing platforms.
Stop by for a live demo of the camera in action.
And if I’m not attending VEW?
Click here to request a quote.
*These Visionix's AI-based products and services are not currently available in the United States.
Editor's note: This story was updated on Sept 4, 2024, to include that the VX 610 has no AI or computer grading available in the United States, and that the Nexy AI is also not available in the United States.